Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-04-14 4:31 pm Sale | 13G | OncoCyte Corporation OCX | PURA VIDA INVESTMENTS LLC | 16,641,824 9.99% | -1,414,450 (-7.83%) | View |
| 2023-04-07 10:38 am Purchase | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS L.P. | 57,131,187 33.3% | 26,918,288 (+89.10%) | View |
| 2023-02-14 1:11 pm Unchanged | 13G | OncoCyte Corporation OCX | PURA VIDA INVESTMENTS LLC | 18,056,274 15.22% | 0 (Unchanged) | View |
| 2023-02-14 11:33 am Purchase | 13G | OncoCyte Corporation OCX | PURA VIDA INVESTMENTS LLC | 18,056,274 15.22% | 5,832,321 (+47.71%) | View |
| 2023-02-14 11:23 am Purchase | 13G | OncoCyte Corporation OCX | AWM Investment Company Inc. | 7,254,222 6.1% | 7,254,222 (New Position) | View |
| 2022-11-23 5:52 pm Purchase | 13G | OncoCyte Corporation OCX | Norfield Capital LLC | 6,600,359 5.5% | 6,600,359 (New Position) | View |
| 2022-07-28 5:06 pm Purchase | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS L.P. | 30,212,899 24.1% | 6,437,935 (+27.08%) | View |
| 2022-05-09 3:23 pm Purchase | 13G | OncoCyte Corporation OCX | BlackRock Inc. BLK | 5,005,216 4.2% | 12,070 (+0.24%) | View |
| 2022-04-18 3:56 pm Purchase | 13G | OncoCyte Corporation OCX | Halle Special Situations Fund LLC | 7,129,456 6% | 7,129,456 (New Position) | View |
| 2022-04-15 5:21 pm Purchase | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS L.P. | 23,774,964 19.99% | 5,939,374 (+33.30%) | View |
| 2022-02-04 4:12 pm Purchase | 13G | OncoCyte Corporation OCX | BlackRock Inc. BLK | 4,993,146 5.4% | 1,398,115 (+38.89%) | View |
| 2021-09-24 4:40 pm Unchanged | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS L.P. | 17,835,590 19.3% | 0 (Unchanged) | View |
| 2021-02-10 3:04 pm Purchase | 13G | OncoCyte Corporation OCX | BlackRock Inc. BLK | 3,595,031 4.6% | 93,000 (+2.66%) | View |
| 2021-02-09 5:10 pm Purchase | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS L.P. | 17,835,590 20.1% | 600,000 (+3.48%) | View |
| 2021-02-02 3:13 pm Purchase | 13G | OncoCyte Corporation OCX | BlackRock Inc. BLK | 3,502,031 5.2% | 3,502,031 (New Position) | View |
| 2021-01-28 3:44 pm Purchase | 13G | OncoCyte Corporation OCX | PURA VIDA INVESTMENTS LLC | 12,223,953 15.54% | 6,527,377 (+114.58%) | View |
| 2021-01-22 4:18 pm Purchase | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS L.P. | 17,235,590 21.6% | 5,078,217 (+41.77%) | View |
| 2021-01-08 5:00 pm Sale | 13D | OncoCyte Corporation OCX | Lineage Cell Therapeutics Inc. LCTX | 3,297,401 4.9% | -968,503 (-22.70%) | View |
| 2020-04-27 5:28 pm Sale | 13D | OncoCyte Corporation OCX | Lineage Cell Therapeutics Inc. LCTX | 4,265,904 6.3% | -1,775,250 (-29.39%) | View |
| 2020-02-14 12:14 pm Purchase | 13G | OncoCyte Corporation OCX | PURA VIDA INVESTMENTS LLC | 5,696,576 9.41% | 2,755,400 (+93.68%) | View |